Remove 2022 Remove Diabetes Remove Outcomes
article thumbnail

CareDx Launches Two Expanded Indications for AlloSure Testing Services

DAIC

Simultaneous pancreas-kidney (SPK) transplants are known to improve the quality of life and long-term survival of patients with insulin dependent diabetes and advanced renal disease. I have witnessed firsthand the significant benefits for patients with diabetes and kidney failure of receiving a pancreas and kidney transplant.

article thumbnail

Cardiometabolic Health Congress (CMHC) To Host  DIETARY STRATEGIES FOR REVERSING TYPE 2 DIABETES: Advances, Perspectives, and Expert Discussions Live Webinar in Honor of the Late Dr. Sarah Hallberg

Cardiometabolic Health Congress

Dr. Hallberg passed in March of 2022 after a 5-year battle with stage IV lung cancer. As an expert on metabolic control and type 2 diabetes (T2D), Dr. Hallberg once gave a TedTalk titled Reversing Type 2 diabetes starts with ignoring the guidelines , which quickly accumulated 8.6

Webinar 105
article thumbnail

CMHC Presents at ADA 2024: Key Findings and Insights

Cardiometabolic Health Congress

Neha Agarwal, PhD, Clinical Director at Cardiometabolic Health Congress , Informa Connect, recently presented significant findings at the 84th American Diabetes Association (ADA) Scientific Sessions. The Diabetes Track will feature: “Precision Medicine in Diabetes” by Jose C.

CME 59
article thumbnail

Abstract 215: A Sweet Indicator: HbA1C and Thrombectomy Outcomes in Hispanics

Stroke: Vascular and Interventional Neurology

IntroductionThere is a higher prevalence of diabetes mellitus type 2 in Hispanics as compared to other ethnic groups in the United States. Diabetes is a risk factor for acute ischemic stroke and also a poor predictor of outcome for many interventional surgeries. or greater. vs. 20.5%; p = 0.048) and stenting (28.4%

article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

This year’s theme, “Advancing Cardiovascular Care for All” brings the latest practice-changing breakthroughs, along with top experts debating and discussing outcomes of highly-anticipated clinical trials. 24 from April 6 - 8, 2024 in Atlanta, GA at the Georgia World Congress Center.

article thumbnail

Abstract WP229: Comparing the Real-World Effects of Once-Weekly Semaglutide and Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcomes, Health Care Resource Utilization, and Medical Costs in Individuals With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Stroke Journal

When compared with placebo, glucagon-like peptide-1 receptor agonists such as once-weekly semaglutide (semaglutide OW T2D) improve cardiovascular outcomes in people with type 2 diabetes (T2D), whereas dipeptidyl peptidase-4 inhibitors (DPP-4is) do not.

article thumbnail

Abstract TP334: Racial Disparities in Functional Outcomes and Stroke Recurrence in Young Patients with Ischemic Stroke

Stroke Journal

Introduction:Studies have reported racial disparities in acute stroke treatment and follow-up care in young patients which lead to less desirable outcomes for minorities. A logistic regression was used to evaluate the odds ratio of favorable functional outcomes (mRS 2) by 90 days. male, covering 57.2% BL, and 20.4% BL, and 20.4%

Stroke 40